United States: How SUPPORT Will Affect Pharma Interactions With DEA

Last Updated: November 1 2018
Article by Jodi L. Avergun

Most Read Contributor in United States, August 2019

The opioid package President Donald Trump signed last week garnered much attention. While it is largely directed at treatment and prevention, it contains several momentous provisions for those companies that manufacture, distribute or dispense opioid medications. This article discusses a few of the more important provisions that are anticipated to affect the pharmaceutical industry in its interactions with the U.S. Drug Enforcement Administration. In short, the act imposes new requirements on wholesale distributors related to handling of controlled substances and increases penalties for failing to comply with the act and, interestingly, imposes quite significant analytical and reporting hurdles on the Drug Enforcement Administration and, to a lesser extent, the U.S. Department of Health and Human Services.

The act codifies the requirement to report suspicious orders and increases the penalties for failure to do so.

First, HR6 codifies what had previously been simply a regulatory requirement that manufacturers and distributors must report to the DEA suspicious orders of controlled substances.1 It also slightly broadens the definition of suspicious orders by defining a "suspicious order" as one that may include "but is not limited to" orders of unusual size, orders deviating substantially from a normal pattern, or orders of unusual frequency. The act mimics the current regulatory requirement that a DEA registrant must design and operate a system to identify suspicious orders, but now also requires that the system comply with applicable federal and state privacy laws. The act also requires that reports must be filed "upon discovering suspicious orders" or a "series of [suspicious] order," and that reports must be sent to both the DEA administrator and the DEA division office where the registrant is located or conducts business.

The DEA has expended vast resources investigating and charging manufacturers, distributors and pharmacy chains with failing to report suspicious orders, and has collected hundreds of millions of dollars in settlements from errant companies. It is unclear how impactful codifying the regulatory landscape will be, but one laudable impact is the requirement that the DEA create a centralized data base to collect — and presumably analyze and report — suspicious order data from the country's thousands of manufacturer and distributor registrants. The act requires the attorney general to establish a centralized database for collecting these reports from industry within one year. It also requires the DEA to report to Congress on its progress in creating the mandatory centralized database as well as an explanation of how the DEA utilizes industry's suspicious order reports both before and after the passage of the act.

Careful analysis and data mining of suspicious order reports could potentially lead to more specific and accurate identification of suspicious orders, which in turn will go a long way to reduce the flow of drugs outside legitimate scientific and medical channels. But it remains to be seen how and whether the DEA will be able to successfully stand up a centralized suspicious order report data base. Certainly one challenge will be that there is no standardized template or communication mode for transmitting suspicious orders. The DEA is expected to publish a notice and petition for rule making regarding suspicious orders by February 2019. Assuming the DEA complies with this deadline, we can expect to see more clarity around both the definition of suspicious orders, and as a result of the act, a form reporting template as well as communication requirements. This will be helpful to industry.

More ominously, the new law increases the penalties for failing to report suspicious opioid orders. The act provides increased civil penalties of up to $100,000 and a criminal fine of up to $500,000 for manufacturers and distributors who fail to report suspicious orders, fail to maintain effective controls against opioid diversion or fail to review ARCOS information.2

The act requires the DEA to share Automated Reports and Consolidated Orders System, or ARCOS, data with regulated industry and state partners.

Manufacturers and distributors are required to report on a monthly basis its acquisitions and dispositions of all controlled substances in Schedules I and II (which include opioids). In apparent response to intense criticism that the DEA has always had in its possession data that would help industry understand the volume of controlled substances being delivered to a pharmacy, the act imposes significant new data sharing requirements on the DEA. Specifically, the new law requires the DEA, within one year from enactment, to publish on a quarterly basis the total number of distributors from which a particular pharmacy buys and the total quantity and type of opioids distributed to each pharmacy or practitioner. This will finally allow manufacturers and distributors to see the total volume a pharmacy gets from each distributor, a critical piece of information to assess whether a particular pharmacy is filling an unusual amount of prescriptions. The provisions further mandate that the DEA share information with regulatory, licensing, attorneys general and law enforcement agencies of states on a semi-annual basis related to amounts, outliers and trends of distributor and pharmacy registrants.

However, the improved data sharing does not come without a price. The new law will punish a manufacturer or distributor who does not review and assess the newly available data. In particular, the law provides that all registered manufacturers and distributors shall be responsible for reviewing the information made available by the attorney general under this subsection and may be penalized if the DEA can prove that drug manufacturers and distributors failed to consider available ARCOS data when determining whether an order for opioids is suspicious.

The act aims to empower pharmacists to refuse to fill suspicious prescriptions.

In recent years, the DEA has focused significant attention on the pharmacist's role in preventing diversion of controlled substances. Regulations under the Controlled Substances Act provide that while "the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner ... a corresponding responsibility rests with the pharmacist who fills the prescription."3 The DEA has indicated through enforcement actions and informal guidance that it interprets this obligation to mean that pharmacists have an obligation to decline to fill suspicious prescriptions and, beyond that, to ensure that no other pharmacists within a single store or drugstore chain fill prescriptions for a suspicious patient or practitioner. This is sometimes called a blanket refusal to fill. Blanket refusals are controversial because many states have regulations that require pharmacists to evaluate each and every prescription individually. Additionally, certain state regulations suggest that if a prescription appears facially valid and is written by a duly licensed practitioner, a pharmacist is required to fill it.

Ostensibly to breach this divide, Section 3212 of the act directs the Department of Health and Human Services to help develop and disseminate materials clarifying the circumstances under which pharmacists may decline to fill controlled substance prescriptions, such as when they suspect the prescriptions are fraudulent, forged or of doubtful, questionable or suspicious origin.

There is no doubt that myriad and conflicting state and federal obligations put pharmacists and the pharmacies that employ them in a challenging position. But law enforcement priorities and the opioid crisis have imposed an ever-increasing expectation on pharmacists to act as a gatekeeper to stop individual suspicious prescriptions but also to share that view widely within their stores, chains and even communities. The act's requirement that HHS educate pharmacists about their rights and responsibilities in this area will hopefully lead to more clear guidance for pharmacists that will empower them to fulfill the gatekeeper role that they clearly play.


[1] See Act, Sec. 3292.

[2] See Sec. 3273(c).

[3] 21 C.F.R. § 1306.04.

Originally published by Law360.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions